 |
156 Diseases |  |
15 Trials |
|
15 Trials |  |
235 News |  |
| «1234 |
- cisplatin / Generic mfg.
Trial termination: Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis (clinicaltrials.gov) - Jan 2, 2014
P3, N=303, Terminated, Sponsor: S. Maria Hospital, Terni
Recruiting --> Terminated; we terminated the study before enrolling 303/560 due to a slow accrual
- cisplatin / Generic mfg.
Enrollment change: Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis (clinicaltrials.gov) - Jan 2, 2014
P3, N=303, Terminated, Sponsor: S. Maria Hospital, Terni
Recruiting --> Terminated; we terminated the study before enrolling 303/560 due to a slow accrual N=560 --> 303
- |||| ondansetron / Generic mfg., aprepitant oral / Generic mfg., dexamethasone injection / Generic mfg.
Trial completion, Surgery: Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients (clinicaltrials.gov) - Dec 17, 2013
P4, N=100, Completed, Sponsor: Scott and White Hospital & Clinic
N=560 --> 303 Recruiting --> Completed
- Decadron (dexamethasone) / Merck (MSD)
Enrollment change: Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting (clinicaltrials.gov) - Nov 7, 2013
P4, N=122, Completed, Sponsor: Sergio Bergese
Recruiting --> Completed N=200 --> 122
- Decadron (dexamethasone) / Merck (MSD)
Trial completion: Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting (clinicaltrials.gov) - Nov 7, 2013
P4, N=122, Completed, Sponsor: Sergio Bergese
N=200 --> 122 Recruiting --> Completed
- | Decadron (dexamethasone) / Merck (MSD)
Trial completion: Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial (clinicaltrials.gov) - Nov 4, 2013
P3, N=1021, Completed, Sponsor: Joseph Roscoe
Recruiting --> Completed Active, not recruiting --> Completed
- || fosaprepitant / Generic mfg.
Enrollment change: A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012) (clinicaltrials.gov) - Oct 20, 2013
P1, N=188, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed N=76 --> 188
- ||||||| aprepitant oral / Generic mfg.
Trial completion: A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208) (clinicaltrials.gov) - Sep 3, 2013
P3, N=307, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=76 --> 188 Active, not recruiting --> Completed
- aprepitant oral / Generic mfg.
Enrollment change: A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients (clinicaltrials.gov) - Aug 20, 2013
P=N/A, N=20, Completed, Sponsor: West Virginia University Healthcare
Active, not recruiting --> Completed N=40 --> 20
- aprepitant oral / Generic mfg.
Trial completion: A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients (clinicaltrials.gov) - Aug 20, 2013
P=N/A, N=20, Completed, Sponsor: West Virginia University Healthcare
N=40 --> 20 Recruiting --> Completed
- ondansetron intravenous / Generic mfg., aprepitant oral / Generic mfg.
Trial withdrawal, Surgery: Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and Vomiting (clinicaltrials.gov) - Aug 7, 2013
P=N/A, N=0, Withdrawn, Sponsor: North Shore Long Island Jewish Health System
Recruiting --> Completed Terminated --> Withdrawn
- ondansetron intravenous / Generic mfg., aprepitant oral / Generic mfg.
Enrollment change, Surgery: Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and Vomiting (clinicaltrials.gov) - Aug 7, 2013
P=N/A, N=0, Withdrawn, Sponsor: North Shore Long Island Jewish Health System
Terminated --> Withdrawn N=19 --> 0
- ||| cyclophosphamide / Generic mfg., docetaxel / Generic mfg.
Enrollment closed, CINV: Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer. (clinicaltrials.gov) - Jun 6, 2013
P4, N=212, Active, not recruiting, Sponsor: Spanish Breast Cancer Research Group
N=19 --> 0 Recruiting --> Active, not recruiting
- |||| ondansetron / Generic mfg., temozolomide / Generic mfg.
Enrollment open, Combination therapy, CINV: Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide (clinicaltrials.gov) - May 8, 2013
P2, N=136, Recruiting, Sponsor: Katy Peters
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| fosaprepitant / Generic mfg.
Trial completion, Surgery: A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148) (clinicaltrials.gov) - Mar 31, 2013
P1, N=98, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Recruiting --> Completed
- ondansetron / Generic mfg., cytarabine / Generic mfg.
Enrollment closed: Ondansetron Versus Aprepitant Plus Ondansetron for Emesis (clinicaltrials.gov) - Mar 21, 2013
P2, N=100, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Recruiting --> Active, not recruiting
- aprepitant oral / Generic mfg.
Enrollment open: A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219) (clinicaltrials.gov) - Feb 28, 2013
P2b, N=260, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- cyclophosphamide / Generic mfg.
Trial termination: Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients (clinicaltrials.gov) - Jan 21, 2013
P3, N=580, Terminated, Sponsor: S. Maria Hospital, Terni
Not yet recruiting --> Recruiting Recruiting --> Terminated; We terminated the study after enrolling 580/900 patients due to a slow accrual
- cyclophosphamide / Generic mfg.
Enrollment change: Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients (clinicaltrials.gov) - Jan 21, 2013
P3, N=580, Terminated, Sponsor: S. Maria Hospital, Terni
Recruiting --> Terminated; We terminated the study after enrolling 580/900 patients due to a slow accrual N=800 --> 580
- ||||||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica
Trial completion: A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting (clinicaltrials.gov) - Jan 15, 2013
P3, N=413, Completed, Sponsor: Helsinn Healthcare SA
N=800 --> 580 Recruiting --> Completed
- |||| Decadron (dexamethasone) / Merck (MSD)
Enrollment open, CINV: A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC) (clinicaltrials.gov) - Jan 7, 2013
P4, N=492, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed Not yet recruiting --> Recruiting
- aprepitant oral / Generic mfg., melphalan / Generic mfg.
Trial completion: Treatment of Chemotherapy-induced Nausea and Vomiting (clinicaltrials.gov) - Dec 11, 2012
P2, N=90, Completed, Sponsor: Uppsala University Hospital
Not yet recruiting --> Recruiting Recruiting --> Completed
- | aprepitant oral / Generic mfg.
New P2b trial: A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219) (clinicaltrials.gov) - Nov 20, 2012
P2b, N=260, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- ||| ondansetron / Generic mfg., temozolomide / Generic mfg.
Trial initiation date, Combination therapy, CINV: Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide (clinicaltrials.gov) - Nov 19, 2012
P2, N=136, Recruiting, Sponsor: Katy Peters
Recruiting --> Completed Initiation date: Sep 2012 --> Dec 2012
- 5-fluorouracil / Generic mfg., gemcitabine / Generic mfg.
Enrollment change: Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer (clinicaltrials.gov) - Sep 27, 2012
P=N/A, N=22, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
Initiation date: Sep 2012 --> Dec 2012 N=57 --> 22
- 5-fluorouracil / Generic mfg., gemcitabine / Generic mfg.
Trial completion: Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer (clinicaltrials.gov) - Sep 27, 2012
P=N/A, N=22, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
N=57 --> 22 Active, not recruiting --> Completed
- mesna / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment closed: Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-?) Release (clinicaltrials.gov) - Aug 5, 2012
P2, N=40, Active, not recruiting, Sponsor: John Haslip
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- cyclophosphamide / Generic mfg.
Trial completion: Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant (clinicaltrials.gov) - Aug 5, 2012
P=N/A, N=40, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ondansetron / Generic mfg., aprepitant oral / Generic mfg., palonosetron intravenous / Generic mfg.
Clinical: Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC) (clinicaltrials.gov) - Jul 11, 2012
P=N/A, N=40, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
- ||||| Decadron (dexamethasone) / Merck (MSD)
New P4 trial, CINV: A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC) (clinicaltrials.gov) - Jul 8, 2012
P4, N=492, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | Emestop (ramosetron hydrochloride) / Samyang Group
Enrollment closed: Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer (clinicaltrials.gov) - Feb 15, 2012
P2, N=41, Active, not recruiting, Sponsor: Hallym University Medical Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| aprepitant oral / Generic mfg.
Trial completion: Re-examination Study of EMEND (Aprepitant) (MK-0869-184) (clinicaltrials.gov) - Dec 21, 2011
P=N/A, N=3546, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Sancuso (granisetron) / Cumberland
Trial suspension: Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer (clinicaltrials.gov) - Dec 13, 2011
P=N/A, N=60, Suspended, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Not yet recruiting --> Suspended
- | Decadron (dexamethasone) / Merck (MSD)
New P4 trial: Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting (clinicaltrials.gov) - Nov 16, 2011
P4, N=122, Completed, Sponsor: Sergio Bergese
- fosaprepitant / Generic mfg.
Enrollment change: Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183) (clinicaltrials.gov) - Nov 1, 2011
P1, N=16, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Suspended N=24 --> 16
- |||| aprepitant oral / Generic mfg.
Enrollment open: Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy (clinicaltrials.gov) - Oct 19, 2011
P2, N=82, Recruiting, Sponsor: University Health Network, Toronto
N=24 --> 16 Not yet recruiting --> Recruiting
- ||||| ondansetron / Generic mfg., temozolomide / Generic mfg.
New P2 trial, Combination therapy, CINV: Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide (clinicaltrials.gov) - Oct 10, 2011
P2, N=136, Recruiting, Sponsor: Katy Peters
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment change: Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients (clinicaltrials.gov) - Sep 13, 2011
P=N/A, N=23, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting N=18 --> 23
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients (clinicaltrials.gov) - Sep 13, 2011
P=N/A, N=23, Completed, Sponsor: M.D. Anderson Cancer Center
N=18 --> 23 Active, not recruiting --> Completed